window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

oral chemotherapy

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Otsuka secures EU approval for Inaqovi combination therapy in acute myeloid leukaemia

    Inaqovi in combination with venetoclax has received an amended European [...]

    June 24, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Otsuka submits EMA application for Inaqovi and venetoclax combination to treat acute myeloid leukaemia

    Otsuka Pharmaceutical Europe has submitted a marketing authorisation application (MAA) [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Meteor Biotech joins South Korea consortium to advance brain organoid commercialisation platform
    Categories: Advanced Therapies, Biotech & Pharma Business, Drug Discovery & Development, Genomics and sequencing, Therapeutic Areas
  • Otsuka secures EU approval for Inaqovi combination therapy in acute myeloid leukaemia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • TRIMTECH raises $14M to advance protein degradation therapies for neurodegenerative diseases
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Drug Discovery & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top